Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
Denali Therapeutics Inc. Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome DNL126 (ETV:SGSH) Phase 1/2 preliminary data presented at 2026 WORLD Symposium™ , supporting plans to pursue an accelerated approval path in Sanfilippo syndrome type A Start-up activities underway for DNL628 (OTV:MAPT) Phase 1b study for Alzheimer's disease and DNL952 (ETV:GAA) Phase 1 study for late-onset Pompe disease TransportVehicle™ platform and clinical pipeline progressing across lysosomal storage disorders and neurodegenerative diseases SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. “In 2025, we made meaningful progress toward delivering urgently needed treatment options for people living with n
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsGlobeNewswire
- Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology DevelopmentGlobeNewswire
DNLI
Earnings
- 2/26/26 - Beat
DNLI
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form S-8
- 2/26/26 - Form 8-K
- DNLI's page on the SEC website